Barghouthi Nadia, Turner Jennifer, Perini Jessica
Department of Endocrinology, West Virginia University, Morgantown, WV, USA.
Department of Medicine, West Virginia University, Morgantown, WV, USA.
Case Rep Endocrinol. 2018 Dec 31;2018:3652602. doi: 10.1155/2018/3652602. eCollection 2018.
To describe a case of invasive ductal carcinoma of the breast in a transgender male receiving testosterone therapy for gender-affirming treatment.
A 28-year-old transgender male receiving intramuscular testosterone was found to have a breast mass on ultrasound after self-exam revealed a palpable breast lump. Ultrasound-guided breast biopsy revealed estrogen receptor/progesterone receptor (ER/PR) negative, human epidermal growth factor receptor-2 (HER-2) positive, invasive ductal carcinoma of the left breast. He underwent neoadjuvant and adjuvant chemotherapy along with bilateral mastectomy. At patient request, his testosterone injections were permanently discontinued.
Fewer than 20 cases of breast cancer in transgender male patients have been reported in medical literature. While studies have shown increased risk of breast cancer in postmenopausal women with higher testosterone levels, data regarding premenopausal women is conflicting and little is known about breast cancer risk in transgender individuals receiving gender-affirming hormone therapy (GAHT), with inconclusive results regarding correlation between testosterone therapy and breast cancer. More research is required to evaluate whether a possible increased risk of breast cancer exists for transgender men receiving gender-affirming therapy.
描述一例接受睾酮治疗以进行性别确认的变性男性患乳腺浸润性导管癌的病例。
一名28岁接受肌肉注射睾酮治疗的变性男性，在自我检查发现可触及乳腺肿块后，超声检查发现乳腺有肿物。超声引导下乳腺活检显示雌激素受体/孕激素受体（ER/PR）阴性、人表皮生长因子受体2（HER-2）阳性，为左乳腺浸润性导管癌。他接受了新辅助化疗和辅助化疗以及双侧乳房切除术。应患者要求，他永久性停止了睾酮注射。
医学文献中报道的变性男性乳腺癌病例少于20例。虽然研究表明睾酮水平较高的绝经后女性患乳腺癌的风险增加，但关于绝经前女性的数据存在矛盾，对于接受性别确认激素治疗（GAHT）的变性个体患乳腺癌的风险知之甚少，关于睾酮治疗与乳腺癌之间的相关性结果尚无定论。需要更多研究来评估接受性别确认治疗的变性男性是否存在可能增加的乳腺癌风险。
